Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16256480 | 0.86 | MAPT (0.53) | FFAR4MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL11647126 | 0.84 | APP (0.56) | MAPTMAPK1TDP1L3MBTL1APP | |
| SCHEMBL31375355 | 0.84 | APP (0.56) | MAPTMAPK1TDP1L3MBTL1APP | |
| SCHEMBL2880445 | 0.82 | MRGPRX4 (0.66) | FFAR4MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL28843836 | 0.82 | FFAR1 (0.59) | MAPTMAPK1TDP1L3MBTL1APP | |
| SCHEMBL6830402 | 0.81 | APP (0.68) | MAPTAPPHTTSMN1; SMN2 | |
| SCHEMBL1421536 | 0.81 | APP (0.68) | MAPK1APPMRGPRX4HTTSMN1; SMN2 | |
| SCHEMBL25081934 | 0.81 | MAPT (0.64) | FFAR4MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL1439758 | 0.81 | PPARD (0.58) | FFAR4MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL1285894 | 0.81 | FFAR4 (0.61) | FFAR4MAPTMAPK1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457639-B2 | Fluorescent regulators of RASSF1A expression and human cancer cell proliferation | GEORGETOWN UNIVERSITY (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457639-B2 | Fluorescent regulators of RASSF1A expression and human cancer cell proliferation | GEORGETOWN UNIVERSITY (US) | 2019-10-29 | — | — | US | disclosed |
| US-10266490-B2 | Radioprotector compounds | GEORGETOWN UNIVERSITY (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3124465-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | Merck Patent GmbH (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-7238671-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238671-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238670-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| WO-2006069154-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
| EP-1615653-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1572892-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004094461-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040127423-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-01 | — | — | US | disclosed |
| US-20030195157-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-16 | — | — | US | disclosed |
| WO-2003033671-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195157-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | GLP1R, IAPP, GIPR | FFAR4 473/4885MAPT 4639/4885MAPK1 1476/4885 |
| US-20040127423-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | GLP1R, IAPP, GIPR | FFAR4 473/4885MAPT 4639/4885MAPK1 1476/4885 |
| US-10266490-B2 | Radioprotector compounds | DDB1, CASP3, BAD | FFAR4 3242/4885MAPT 4589/4885MAPK1 3663/4885 |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | FFAR4 101/4885MAPT 4254/4885MAPK1 239/4885 |
| US-10457639-B2 | Fluorescent regulators of RASSF1A expression and human cancer cell proliferation | RASSF5, RASSF2, MKI67 | FFAR4 4530/4885MAPT 4658/4885MAPK1 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.